Lung cancer patients undergoing immunotherapy may be at risk for developing life-threatening toxicities. Find out how you can manage them with Dr. Jacob Sands and Dr. Aliyah Pabani, Clinical Assistant Professor in the Department of Medicine at the University of Calgary and Director of the Alberta Immunotherapy Database.

From disease-related factors to the latest clinical trial data, there’s a lot to consider when selecting a therapy for patients with ER+/HER2- metastatic breast cancer. Here with Dr. Charles Turck to break down the key factors that can guide our treatment selections is breast medical oncologist Dr. Megan Kruse from the Cleveland Clinic in Ohio.

The future is looking bright for patients with multiple myeloma as more therapies have emerged over the years. So how can multidisciplinary teams continue to provide the best care for their patients? Tune in with Dr. Charles Turck as he speaks with Dr. Morie Gertz, Hematologist at the Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, and Dr. Aaron Rosenberg, Associate Professor in the Hematology and Oncology Department at the UC Davis Comprehensive Cancer Center in Sacramento, California.

Obstacles with platinum rechallenge could lead to treatment burden, but a second-line alternative therapy could be a better option for some of our patients. To learn more, Dr. Charles Turck is joined by Drs. Jacob Sands and Joshua Sabari to share their insights on this therapy for patients with small cell lung cancer.

Treatment for lung cancer can be complex, but PL-L1 expression and tumor mutational burden might help us select the best treatment for our patients. What do we need to know about the role of these biomarkers in the treatment of lung cancer? To discuss this, Dr. Jacob Sands is joined by Dr. Biagio Ricciuti, a medical oncologist at the Dana-Farber Cancer Institute.

Cancer remains the second-leading cause of death in the U.S., creating an urgent need to detect cancer at earlier stages when outcomes are better. With the emergence of novel multi-cancer screening technologies, the potential public health impact may be substantial. Given these advances, is it time to rethink the way clinical trials are designed to assess the effectiveness of these screening technologies? Joining Dr. Charles Turck to discuss how we can utilize surrogate endpoints to evaluate the efficacy of cancer screening modalities is Dr. Eric Klein, a distinguished scientist at GRAIL.

HPV is the leading cause of oropharynx cancers in the United States, but with no screening tools currently available, how we can detect this cancer in our patients? Host Dr. Jacob Sands speaks with a leader in the field, Dr. Eleni Rettig, an Assistant Professor of Otolaryngology-Head and Neck Surgery at Harvard Medical School, to share risk factors and explore emerging diagnostic tools.

Can cancer survivorship models help clinicians navigate the road ahead with their cancer patients? Here to share insights on unmet needs, opportunities, and symptom burden for cancer survivorship care is Dr. Michelle Mollica, the Deputy Director at the National Cancer Institute’s Office of Cancer Survivorship.

The treatment landscape for metastatic breast cancer is rapidly evolving. With all of these new advancements and research, it can be helpful to review the available treatment options and best practices for selecting an approach after treatment with a CDK4/6 inhibitor has failed. That’s why Dr. Charles Turck discusses how we can treat patients with metastatic breast cancer in the second- and third-line setting with Dr. Hope Rugo, who’s a Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco Hellen Diller Family Comprehensive Cancer Center.

To learn more about key considerations for prehabilitation, Nurse Practitioner Lisa Parks from the Ohio State University Wexner Medical Center in Columbus, Ohio recaps important factors to keep in mind for cancer patients undergoing surgery.